Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants
1 other identifier
observational
4,000
1 country
1
Brief Summary
Genetic mutations has been proved to be associated wth the onset of cardiomyopathy. In the present study, we intend to identify new related variants or genes. From March, 2003 to November, 2017, patients diagnosed as cardiomyopathy were consecutively recruited, and their sampled were drawn from peripheral blood. Paired control group were also enrolled. The whole exome sequencing was used to find out the variants associated with the onset of cardiomyopathy and its prognosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2003
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 3, 2003
CompletedFirst Submitted
Initial submission to the registry
November 1, 2018
CompletedFirst Posted
Study publicly available on registry
November 27, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2025
CompletedFebruary 17, 2023
February 1, 2023
22.7 years
November 1, 2018
February 15, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Cardiovascular death confirmed by death comfirmation or interview with the relatives
Death from cardiovascular causes and any unknown death unless there was another certain cause
up to 24 months
Heart transplantation confirmed by medical record
Heart transplantation within 24 months
up to 24 months
Secondary Outcomes (2)
All cause death confirmed by death comfirmation or interview with the relatives
up to 24 months
Heart failure recurring confirmed by medical record
up to 24 months
Other Outcomes (1)
Readmission because of cardiovascular diseases confirmed by medical record
up to 24 months
Eligibility Criteria
hospitalized patients with cardiomyopathy will be enrolled in this study
You may qualify if:
- · Patients diagnosed as cardiomyopathy according to the definition of American Heart Association
You may not qualify if:
- Uncontrolled hypertension significant valvular disease
- Mild ischemic heart disease
- Significant systemic infection
- Thyroid-induced cardiomyopathy
- Excessive alcohol consumption
- Precious cancer treatment including irradiation
- Refusal to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Tongji Hospitallead
Study Sites (1)
Tongji Hospital
Wuhan, Hubei, 430030, China
Related Publications (1)
Li S, Sun Y, Hu S, Hu D, Li C, Xiao L, Chen Y, Li H, Cui G, Wang DW. Genetic risk scores to predict the prognosis of chronic heart failure patients in Chinese Han. J Cell Mol Med. 2020 Jan;24(1):285-293. doi: 10.1111/jcmm.14722. Epub 2019 Oct 31.
PMID: 31670483DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Dao Wen Wang, Doctor
Tongji Hospital,Wuhan, Hubei, China, 430030
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
November 1, 2018
First Posted
November 27, 2018
Study Start
March 3, 2003
Primary Completion
October 31, 2025
Study Completion
October 31, 2025
Last Updated
February 17, 2023
Record last verified: 2023-02